Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans
Cost Savings Of $20m Annually Targeted; Portfolio Also Rationalized
Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, New York.
You may also be interested in...
Sun Pharma’s key antitrust trial kicks off and Lannett awaits word from the US FDA for its generic Advair filing during a busy first month of 2022, which also features updates from the annual J.P. Morgan Health Care Conference.
With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio.
Lannett continues to eye the potential launch of its partnered Advair generic next year, after the lucrative respiratory asset was accepted for filing by the FDA.